41513-02-4

Basic information

• Product Name: 4-BROMO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE
• Synonyms: 4-BROMO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE
• CAS NO: 41513-02-4
• Molecular Formula: C₈H₃BrF₃NO
• Molecular Weight: 266.01
• Mol File: 41513-02-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 115 °C10 mm Hg(lit.)
• Flash Point: 230 °F
• Appearance: /
• Density: 1.699 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.524(lit.)
• CAS DataBase Reference: 4-BROMO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE(41513-02-4)
• EPA Substance Registry System: 4-BROMO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE(41513-02-4)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 41513-02-4(Hazardous Substances Data)

Upstream product

• 503-38-8 trichloromethyl chloroformate 
• 393-36-2 4-bromo-3-(trifluoromethyl)aniline 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 22546-27-6 C₁₀H₁₁BrF₃N₃O 
• 22546-45-8 C₉H₉BrF₃N₃O 
• 284462-44-8 4-(4-amino-3-chloro-phenoxy)-pyridine-2-carboxylic acid methylamide 
• 284462-83-5 4-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-3-chloroaniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-92-6 3-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-4-methylaniline 
• 1220892-55-6 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-((2-(N-methylaminoformyl)-5-methylpyrrol-4-yl)oxy)phenyl)urea 
• 1220892-52-3 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylaminoformoxyl)-4-(7-aminoisoquinolyl)oxy)phenyl)urea 
• 1220892-43-2 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylaminoformoxyl)-4-(6-methoxyquinolinyl)oxy)phenyl)urea 
• 1220892-49-8 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylaminoformoxyl)-5-(4-methoxypyrimidinyl)oxy)phenyl)urea 
• 1220892-46-5 N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylaminoformoxyl)-4-(7-fluoroquinazolinyl)oxy)phenyl)urea 
• 23122-25-0 (4-Bromo-3-trifluoromethyl-phenyl)-carbamic acid 3-methoxycarbonylamino-phenyl ester 

Relevant articles and documents

N-substituted 2-isonicotinoylhydrazinecarboxamides-new antimycobacterial active molecules

This report presents a new modification of the isoniazid (INH) structure linked with different anilines via a carbonyl group obtained by two synthetic procedures and with N-substituted 5-(pyridine-4-yl)-1,3,4-oxadiazole-2-amines prepared by their cyclisation. All synthesised derivatives were characterised by IR, NMR, MS and elemental analyses and were evaluated in vitro for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv, Mycobacterium avium 330/88, Mycobacterium kansasii 235/80 and one clinical isolated strain of M. kansasii 6509/96. 2-Isonicotinoyl-N-(4- octylphenyl)hydrazinecarboxamide displayed an in vitro efficacy comparable to that of INH for M. tuberculosis with minimum inhibitory concentrations (MICs) of 1-2 μM. Among the halogenated derivatives, the best anti-tuberculosis activity was found for 2-isonicotinoyl-N-(2,4,6-trichlorophenyl) hydrazinecarboxamide (MIC = 4 μM). In silico modelling on the enoyl-acyl carrier protein reductase InhA confirmed that longer alkyl substituents are advantageous for the interactions and affinity to InhA. Most of the hydrazinecarboxamides, especially those derived from 4-alkylanilines, exhibited significant activity against INH-resistant nontuberculous mycobacteria. gfjh+l;kfldf.

HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF

The present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds of the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole or pyrimidine, and the substituent is halogen, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, C1-5haloalkoxy, C1-5alkylamino, C1-5haloalkylamino, amino or nitryl; R1 is C1-5alkyl; R2 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; and R3 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy. The compound of the present invention and the pharmaceutically acceptable salt thereof can be used for treating tumor or leukemia.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.